Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 18;18(7):sfaf184.
doi: 10.1093/ckj/sfaf184. eCollection 2025 Jul.

Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease

Venera Bytyqi  1 , Dennis Kannenkeril  1 , Axel Schmid  2 , Kristina Striepe  1 , Agnes Bosch  1 , Marina V Karg  1 , Mario Schiffer  1 , Michael Uder  2 , Roland E Schmieder  1
Affiliations

Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease

Venera Bytyqi et al. Clin Kidney J. .

Abstract

Backgroun: Sympathetic overactivation is associated with numerous pathologies, including arterial hypertension, diabetes, metabolic syndrome and chronic kidney disease (CKD). Renal denervation (RDN) has emerged as an adjacent therapy for the management of hypertension. By modulating sympathetic activity in the whole body, RDN has shown conflicting results regarding insulin secretion and glucose homeostasis. The aim of this study is to analyse the impact of RDN on glycaemic control in patients with CKD.

Methods: A total of 155 hypertensive patients with (n = 45) or without CKD (n = 110) were included in this post hoc analysis. All patients underwent radiofrequency-, ultrasound- or alcohol injection-based RDN. Fasting plasma glucose (FPG) and haemoglobin A1c levels were measured at baseline, 3 months and 6 months after RDN in parallel with the office and 24-h ambulatory blood pressure. CKD was defined either by clinical diagnosis, an estimated glomerular filtration rate (eGFR) of 15-59 ml/min/1.73 m2 and/or A2/A3 albuminuria in hypertensive patients, repeatedly confirmed, or several of these criteria.

Results: In the total study cohort, FPG decreased by 5.1 ± 29.1 mg/dl (P = .032) and by 7.9 ± 32.7 mg/dl (P = .003) at 3 and 6 months after RDN, respectively. The change in FPG levels was related to the change in 24-h systolic BP (r = 0.286, P = .008) 3 months after RDN. Among patients with CKD, FPG levels decreased by 13.5 ± 43.5 mg/dl at 3 months (P = .043) and by 17.1 ± 45.2 mg/dl at 6 months (P = .015) following RDN. These reductions were greater compared with the non-CKD group (P = .021 and P = .024, respectively). After excluding patients on oral antidiabetic or insulin therapy, patients with CKD (but not those without CKD) exhibited a reduction in FPG levels of 6.7 ± 15.3 mg/dl (P = .043) at 6 months post-RDN. No significant changes were observed in eGFR in either group.

Conclusion: We observed that FPG levels improved to a greater extent in hypertensive patients with CKD after RDN. Thus RDN may have a broader therapeutic impact beyond blood pressure reduction in CKD patients.

Keywords: chronic kidney disease; glucose metabolism; renal denervation.

PubMed Disclaimer

Conflict of interest statement

V.B., D.K., A.S., K.S., M.K., M.S., and M.U. declare that they have no conflicts of interest with respect to this study. R.E.S. reports the following conflicts of interest: institutional grants from Medtronic, Recor Medical, Ablative Solutions, and Sonivie/Boston; speaker and adviser bureau: Medtronic and Recor Medical. A.B. received a travel grant from Recor Medical.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
Correlation of the change in FPG and the change in 24-h ambulatory systolic BP 3 months after RDN. Data are presented as mean ± SD.
Figure 2:
Figure 2:
Changes in FPG levels 3 and 6 months after RDN in the CKD and non-CKD subgroups. Data are presented as mean ± SD.
See this image and copyright information in PMC

References

    1. Esler M. Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases. J Cardiovasc Pharmacol 1995;26(Suppl 2): S24–8. 10.1097/00005344-199512020-00004 - DOI - PubMed
    1. Mancia G, Grassi G, Giannattasio C et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999;34:724–8. 10.1161/01.HYP.34.4.724 - DOI - PubMed
    1. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010;90:513–57. 10.1152/physrev.00007.2009 - DOI - PubMed
    1. Esler M, Lambert E, Schlaich M. Point: chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol 2010;109:1996–8; discussion 2016. 10.1152/japplphysiol.00182.2010 - DOI - PubMed
    1. Esler M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol 2010;108:227–37. 10.1152/japplphysiol.00832.2009 - DOI - PubMed